Results for fourth quarter and preliminary results for Medistim for 2018

It was a sales record for both a quarter and for a year. Sales for the quarter ended at MNOK 97.0 (MNOK 82.2), a 19.1 % growth. Sales for 2018 ended at MNOK 325.9 (MNOK 301.5), a growth of 8.1 %. Currency neutral sales of own products increased with 25.5 % for the quarter. For 2018, currency neutral growth in sales of own products was 10.0%. EBIT for the quarter ended at MNOK 27.8 (MNOK 16.4), a 69.6 % growth. For 2018, EBIT ended at MNOK 74.0 (MNOK 65.5) a 13.0 % growth. USA drives growth and there was a record quarter in the US with a 43.4 % sales growth. Currency neutral growth for the year was 10 %. There was also a solid growth in sales in Asia with 144 % for the quarter and 43 % for the year. Earnings per share ended at NOK 3.14 (NOK 2.62) a 19.8 % increase. The Board suggests a dividend of NOK 2.25 per share (NOK 2.00), a 12.5 % increase.